Since the early 1980s, adjuvant tamoxifen therapy has been commonly used in the treatment of early stage breast cancer to improve survival and to reduce the incidence of contralateral breast cancer among postmenopausal women (1). However, the estrogenic effect of tamoxifen on the uterus (2) has been reported to increase the risk of uterine corpus cancer by twofold to threefold (3-6). Recently, an elevated risk of gastrointestinal cancer, particularly colorectal and stomach cancers, was associated with tamoxifen therapy in clinical trials (7). Because late effects of tamoxifen could adversely affect the risk-benefit ratio in ongoing chemoprevention trials, we evaluated the risk of second cancers among 87 323 women with breast cancer reported to the Surveillance, Epidemiology, and End Results (SEER) Program 1 (8). To select women who were most likely to have received tamoxifen, we included patients with breast cancer who were 50 years of age or older, who were diagnosed with early stage disease (i.e., localized or regional) from 1980 through 1992, and who survived at least 2 months (n = 101 930). Since many women given chemotherapy also received steroids, which are classified as hormones in SEER, we excluded those individuals from the analysis (n = 14 607).
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Of the remaining 87 323 women, 14 358 were known to have received hormones for their first course of therapy (designated as the tamoxifen group, since approximately 90%-95% of these patients received tamoxifen [Hankey B, Harlan L: personal communication]), whereas 72 965 women were not known to have received hormones (the no/unknown tamoxifen group). Observed-toexpected ratios (O/E) of second cancers were calculated using standard methods 2 (9, 10) .
Patients with breast cancer initially treated with tamoxifen developed second cancers at a rate slightly higher than that expected in the general population (O/E =1.12; 95% confidence interval [CI] = 1.03-1.21) and identical to that experienced by patients with no/unknown tamoxifen therapy (O/E = 1.12; 95% CI = 1.09-1.15) ( Table 1) . Significant excesses of uterine corpus cancer were seen in both treatment groups, with higher risks following tamoxifen therapy (O/E = 2.03; 95% CI = 1.59-2.55 versus O/E = 1.23; 95% CI = 1.11-1.36). We observed little difference in the severity of grade or stage of uterine corpus cancer on the basis of initial therapy (Table 1) , in contrast with a previous report suggesting a tendency toward higher grade lesions following tamoxifen treatment (11) . Of the 73 women who developed uterine corpus cancer after tamoxifen therapy, six died of this cancer. The actuarial risk of uterine corpus cancer among postmenopausal women after adjuvant tamoxifen therapy was 1.8% at 10 years, compared with 0.9% expected in the general population.
Cancers of the colon and rectum were not in excess following tamoxifen therapy (O/E = 1.04; 95% CI = 0.83-1.30 and O/E = 1.02; 95% CI = 0.66-1.49, respectively), and stomach cancer was not significantly increased (O/E = 1.23; 95% CI = 0.69-2.03), in contrast svith the findings of a recent report (7) . Tamoxifen therapy appeared to decrease the risk of contralateral breast cancer (O/E= 1.12; 95% CI = 0.96-1.30 versus O/E = 1.62; 95% CI = 1.55-1.69), and a more detailed report of this result is planned. Women in the no/unknown tamoxifen group had a statistically significant lower risk of leukemia and of cancers of the liver, lung, and brain (Table 1) .
To sharpen the treatment comparisons, we evaluated a subgroup of women for whom adjuvant tamoxifen was infrequently used, so that misclassification of therapy would be small. Among 17 952 patients with localized breast cancer initially treated between 1980 and 1984, the risk of uterine corpus cancer was nearly identical to that experienced in the general population (O = 121 and O/E = 0.99; 95% CI = 0.82-1.19). This finding suggests that at least part of the excess risk observed in the no/unknown tamoxifen group is related to tamoxifen therapy not reported to the SEER Program.
Among tamoxifen-treated patients, the risk of all second cancers, excluding contralateral breast cancer, was significantly increased among survivors of 5 or more years (O/E = 1.32; 95% CI = 1.02-1.68), whereas no excess cancer risk was found for the no/unknown tamoxifen group in this follow-up interval (O/E = 0.96; 95% CI = 0.90-1.02) ( Table 2) . A notable increase in uterine corpus cancer (O/E = 3.59; 95% CI = 1.96-6.02) and a nonsignificant excess of stomach cancer (four cases; O/E = 2.61; 95% CI = 0.70-6.69) were observed 5 years or more after breast cancer diagnosis among women who received tamoxifen therapy.
Although the number of patients with breast cancer evaluated in this study is large, few tamoxifen-treated patients have been followed for more than 10 years, limiting our ability to evaluate long-term survivors. Other limitations include a lack of detailed information on initial and subsequent therapy and an absence of data on other factors affecting second cancer risk, such as menopausal estrogen use and hysterectomy.
Our results support the link between tamoxifen therapy and subsequent de- •Tamoxifen group = patients given hormones for initial therapy; no/unknown tamoxifen group = no mention of hormones for initial therapy in medical records.
fNot all second cancer sites are listed; therefore, individual sites do not sum to totals. Grades 1 and 2 = 59%; grades 3 and 4 = 25%; unknown grade = 16%; stage distribution: localized (78%), regional (12%), distant (4%), and unknown (6%). §Grades 1 and 2 = 63%; grades 3 and 4 = 21%; unknown grade = 16%; stage distribution: localized (76%), regional (11%), distant (8%), and unknown (5%). velopment of uterine corpus cancer that has been described in previous investigations (3-7) . However, we found little evidence that tamoxifen treatment increases the incidence of colorectal or stomach cancer significantly, as reported by Rutqvist et al. (7) . Liver cancer risk was not elevated, despite evidence that tamoxifen is a liver carcinogen in rats (72). Further studies of breast cancer survivors are needed to monitor site-specific risks of cancer over time in relation to total dose, dose intensity, and duration of tamoxifen use. 
